3. IIM - Epidemiology Rare, estimated annual incidence 5-10/million, estimated prevalence ~ 60/million. PM and DM peak in prevalence in childhood (5- 15yrs) and mid-life (30-50yrs); IBM peaks after age 50. Females are preferentially affected (~2-3:1) in all forms except in IBM (female:male~1:3).

4. IIM - Epidemiology African-Americans may be at increased risk for IIM and poorer outcomes compared to Caucasians. All races on all continents are affected. Anecdotal clustering of IIM onset in time and space suggest strong environmental influences.

5. IIM – Systemic manifestations General manifestations:fatigue, fever, weight loss. Musculoskeletal: myalgia, muscle tenderness and weakness. Arthralgia, arthritis, contractures. Dermatologic:Photosensitive rashes and edema. Vasculitis with infarcts and ulceration. Subcutaneous inflammation (panniculitis) and calcification.

6. IIM – Systemic manifestations Gastrointestinal: oropharyngeal involvement with tongue weakness and voice changes; dysphagia and reflux. Pulmonary:Atelectasis, cough. Interstitial lung disease. Aspiration. Cardiovascular:Tachyrhythmias and other conduction abnormalities. Congestive heart failure from myocarditis or cor pulmonale. Raynaud.

19. IIM - Evaluation Careful history and physical examination to define: 1.The time\tempo of symptom onset and progression. 2.The exact nature of the problems and associated factors. 3.Medical and family history. 4.Muscle bulk/strength, rashes, cardiac, pulmonary, GI findings. 5.Environmental exposures temporally associated.

20. IIM - Evaluation Laboratory evaluation directed by the above: 1.Muscle enzymes, serologies, tests to R/O other diseases. 2.Radiographic studies, muscle MRI. 3.EMG, biopsies of skin, muscle, possibly other tissues. 4.Special serologic or genetic studies depending upon results from the above.

21. IIM – Laboratory abnormalities Sarcoplasmic enzymes (CPK, LDH, ALT, AST, aldolase) – useful in assessing myositis activity. CPK MB fraction – correlates with diseases activity and is not usually indicative of cardiac involvement unless the ratio of CK-MB/total CK rapidly increases. ESR/CRP – elevated in <30% of pts. ANA – positive in 60-90% of pts; best single lab discriminator of IIM from other myopathies.

22. Causes of elevated serum CPK enzyme activity Physical trauma or muscle stress. 1.Any muscle trauma – falls, EMG studies, surgery, muscle bipsy, IM injection. 2.Strenuous, prolonged exercise-marathon running, forced marching. Drug effects 1.On muscle itself – clofibrate, ethanol, amphetamines, heroin. 2.On CK metabolism/clearance-phenobarbital, morphine, diazepam.

23. Causes of elevated serum CPK enzyme activity Diseases 1.Directly affecting muscle-non inflammatory myopathies of all kinds, MI, malignant hyperthermia, infectious myopathies, IIM. 2.Affecting blood supply to muscle-emboli to muscle, vasculitis,prolonged immobilization. 3.Affecting the CNS-cerebral ischemia, trauma,infections. Possible familial cases in African-Americans.

27. Myositis –specific autoantibodies (MSA) 1.Anti-synthetases – Jo 1(anti histidyl tRNA synthetase). 2.Anti-signal recognition particle (SRP). 3.Anti-Mi-2. They are directed at conserved conformational epitopes on phosphorylated, cytoplasmic ribonucleoprotein particles involved in translation and present in all cells.

28. MSA They inhibit the function of the protein they target. They appear to arise months prior to myositis onset, are antigen driven, vary in titer with myositis disease activity and occasionally become negative after prolonged remission.

29. Associations of the MSA Anti-synthetases (Jo1): Arthritis, interstitial lung disease, fevers, mechanic’s hand, Raynaud’s. Acute onset, severe disease. Moderate response to therapy. Prognosis poor; 70% 5-yrs survival. Frequency in IIM 25-30%.

30. Associations of the MSA Anti-SRP: Cardiac involvement, myalgias, mostly in black females. Very acute onset, very severe disease. Poor response to therapy. Poor prognosis – 25% 5 yrs survival. Frequency in IIM – 5%.

31. Associations of the MSA Anti-Mi-2: Classic dermatomyositis. Acute onset. Mild disease. Good response to therapy Good prognosis. Nearly 100% 5 yrs survival/ Frequency in IIM 5-10%.

32. IIM - pathogenesis Polymyositis and inclusion body myositis may be more cellularly mediated (CD8+ T cells). Dermatomyositis may be more humorally mediated (B cells).

33. IIM – Activity evaluation 1.Muscle strength – grading: 5 – normal power resistance. 4 – power decreased but muscle contraction possible against resistance. 3 – muscle contraction against gravity only. 2 – muscle contraction possible only when gravity is eliminated. 1 – contraction without motion. 0 – no contraction.

34. IIM – Activity evaluation 2. CPK levels. 3.EMG: fibrillations, positive sharp waves, short small polyphasic motor units, high frequency repetitive discharges, normal nerve conduction velocities. 4.Muscle biopsy: myofiber degeneration/regenaration, MNC infiltrates, perifascicular atrophy.

35. IIM – Activity evaluation 4.MRI: T1-weighted images – chronic changes in muscles, atrophy. T2 – weighted and STIR images – active inflammation. Biopsy is taken from a weak muscle, without atrophy, not damaged by EMG, injection, etc.

36. Poor prognostic factors in Myositis Based on demographic features: 1.Age : older. 2.Gender: female. 3.Race: black. Based on signs-symptoms: 1.Fever, dysphagia, severe myositis. 2.Cardiac, pulmonary or GI involvement. 3.Delay to diagnosis and treatment. 4.Failure to induce remissin.

37. Poor prognostic factors in Myositis Based on clinical or serologic group: 1.Clinical groups: polymyositis, cancer-associated or inclusion body myositis. 2.Serologic groups: anti-synthetases or anti-SRP autoantibodies.

38. Therapy Steroids 1-2mg/kg/d. Cytotoxic: MTX, AZT, cytoxan IVIG Plaquenil (rash). Rehabilitation and physical therapy.